Eli Lilly has announced its agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, while Biogen is set to purchase Apellis Pharmaceuticals for approximately $6.1 billion. These transactions highlight a significant trend in the pharmaceutical industry towards consolidation, particularly in the realms of neurology and immunology. Centessa, based in the U.K. and Boston, is advancing a pipeline of orexin receptor 2 (OX2R) agonists aimed at treating sleep disorders, with its lead candidate, cleminorexton, showing promising Phase IIa trial results.
The acquisition by Lilly is expected to enhance its neuroscience portfolio, leveraging Centessa’s innovative approach to sleep-wake cycle disorders. The deal includes a substantial upfront cash payment and contingent value rights tied to future regulatory milestones, indicating Lilly’s confidence in the therapeutic potential of Centessa’s pipeline. Meanwhile, Biogen’s acquisition of Apellis aims to strengthen its position in the nephrology market, building on the success of existing therapies like Empaveli and Syfovre. Biogen anticipates that this acquisition will enhance its revenue growth and expand its patient reach, reflecting a strategic move to bolster its therapeutic offerings in rare diseases.
Use the database as your supply chain compass →
